As new findings emerge about the contribution of tumor cell heterogeneity to tumor progression, drug resistance, and metastasis, a deeper understanding of the features that regulate EWS::FLI1 activity may inform the development of targeted therapies that can moderate them. The gene discussed is FLI1; the disease is neoplasm.